Cosponsored by Novozymes Biopharma Inc.
Saturday, July 12, 08:45 – 17:00
Organizers: Kenneth Howard, Aarhus University, Denmark, and Daniel Shelly, Novozymes Biopharma US, Inc., U.S.A.
Albumin is the most abundant human plasma protein that exhibits prolonged circulatory half-life and a predominant role in extracellular and intracellular transport of nutrients. Exploitation of these properties can be utilized for delivery of drug cargos and a paradigm shift in control of drug extended half-life and targeted delivery. This workshop assembles global leaders from both academia and industry in a unique forum to present and discuss the application of albumin in drug delivery. Biological mechanisms relevant for albumin drug delivery capabilities such as molecule binding, cellular receptor engagement and recycling, and its tuning through recombinant technology for modulation of pharmacokinetics are addressed. Clinical development and commercial albumin-based drug products such as albumin-binding prodrugs, genetic fusions, and nanoparticles are then described that highlight its emergence as the next-generation protein therapeutic.
Speakers subject to change
|08:45 – 09:00||Welcome and Introductions||Kennth Howard, Aarhus University, Denmark|
|09:00 – 09:40||The Neonatal Fc Receptor (FcRn): A Controller of Albumin Homeostasis||Jan Terje Andersen, Oslo University, Norway|
|09:40 – 10:20||Pharmacokinetics of Human Serum Albumin Variants||Masaki Otagiri, Sojo University, Japan|
|10:20 – 10:50||Break|
|10:50 – 11:30||Clinical Impact of Albumin on Drug Delivery in Oncology-Albumin-Binding Prodrugs||Felix Kratz, macromolecular Prodrugs, Tumor Biology Ctr, Germany|
|11:30 – 12:10||Engineered Albumins for the Enhancement of Drug Delivery||Jason Cameron, Novozymes Biopharma UK, Ltd., United Kingdom|
|12:10 – 13:15||Lunch Break|
|13:15-13:55||Albumin-Based Extended Half-Life Studies||Stefan Schulte, CSL Behring, U.S.A.|
|13:55 – 14:35||Prolonged Action of Albumin Binding Insulin: The Insulin Binding Analogue for Diabetes Treatment||Ib Jonassen, Novo Nordisk A/S, Denmark|
|14:35 – 15:00||Break|
|15:00 – 15:40||Albumin Nanoparticle-Based Drug Delivery||Neil Desai, Celgene, U.S.A.|
|15:40 – 16:20||Tregitope-Albumin Fusion||Leslie Cousens,EpiVax, U.S.A.|
|16:20 – 17:00||Roundtable Discussion and Closing Remarks|